Hesperidin Alleviates Cisplatin-Induced Impairment in Adult Male Albino Rat's Submandibular Gland Through Activation of Secretory Complex Stem Cells (Histological, Immunohistochemical and Biochemical Study) | ||||
| Egyptian Journal of Histology | ||||
| Article 14, Volume 47, Issue 1, March 2024, Page 199-222 PDF (17.76 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejh.2022.172950.1804 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ola Abd Elatef Yahia1; Samar Adel Asker2; Wafaa Saad Hamed1; Nawal Awad Hasanin3; Nahla Reda Sarhan  4
| ||||
| 1Medical Histology and Cell biology Department, Faculty of Medicine, Mansoura University | ||||
| 2Department of Histology and Cell Biology, Faculty of Medicine, Mansoura University, Egypt Medical Histology and Cell biology Department, Faculty of Medicine, 6th of October University | ||||
| 3medical histology and cell biology department, faculty of medicine, Mansoura University | ||||
| 4Medical Histology and Cell biology department faculty of medicine Mansoura University | ||||
| Abstract | ||||
| Introduction: Cisplatin chemotherapy targets many tumors. However, it affects the submandibular gland causing its hypofunction. Hesperidin has antioxidant and anti-inflammatory actions. Aim of the Work: Was to evaluate the biochemical and histological alterations caused by two regimens of cisplatin application on rat’s submandibular gland and to assess the effect of hesperidin against these changes. Materials and Methods: 70 adult male albino rats were divided into 4 groups. Group I; control rats, Group II was given hesperidin (100mg/kg/day) orally from day 1 until the experiment end. Group III received single high cisplatin dose (intraperitoneally 12mg/kg) on 8th day and subdivided into subgroup IIIa that received cisplatin only and IIIb received cisplatin + hesperidin as group II. Group IV received multiple low cisplatin doses (intraperitoneally 6mg/kg) once a week starting from 8th day and subdivided into subgroup IVa that received cisplatin only and IVb received cisplatin + hesperidin as group II. Submandibular glands were dissected out and processed for biochemical, histological and immunohistochemical studies. c-Kit was used as a stem cell marker. Results: Subgroups IIIa & IVa showed biochemical, histological, and ultrastructural changes that was more marked in IIIa. There was a significant elevation of malondialdehyde and reduction of antioxidant enzyme activities, disturbance of gland architecture, acinar and duct cell degeneration, significant elevation in % area of collagen fibers and significant reduction in % area of c- kit immune reaction. Subgroups IIIb and IVb showed improvement in the histological picture of the gland with a significant increase in % area of c- kit immune reaction. Conclusion: Cisplatin causes changes in submandibular gland being more marked with the single high dose. Hesperidin partially alleviates these changes through its antioxidant action and enhanced activation of secretory complex stem cells. So, hesperidin can be used clinically with chemotherapy to prevent its side effects. | ||||
| Keywords | ||||
| Cisplatin; c-Kit; hesperidin; stem cells; submandibular gland | ||||
|
Statistics Article View: 235 PDF Download: 155 |
||||
